PRAX-562

DRUG2 trials

Sponsors

Praxis Precision Medicines Inc., Praxis Precision Medicines

Conditions

SCN2A EncephalopathySCN2A and SCN8A developmental and epileptic encephalopathy (SCN2A DEE and SCN8A DEE)SCN8A Encephalopathy

Phase 2

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

Active, not recruitingNCT05818553

Praxis Precision MedicinesSCN2A Encephalopathy, SCN8A Encephalopathy

Start: 2023-08-02End: 2027-03-01Target: 77Updated: 2026-01-29

A Phase 2, Double-Blind, Randomized Clinical Trial to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension

SuspendedCTIS2022-502298-41-00

Praxis Precision Medicines Inc.SCN2A and SCN8A developmental and epileptic encephalopathy (SCN2A DEE and SCN8A DEE)

Start: 2023-08-23Target: 70Updated: 2026-01-21